Geron Corporation (GERN) is an American biopharmaceutical company. Its imetelstat drug candidate is in Phase 3 clinical trials and has been granted Fast Track designation by the FDA. Geron plans to apply for marketing approval for the drug candidate in the U.S. in 2023 and also plans to seek marketing authorization in Europe. Let’s take a look at Geron’s latest financial performance, corporate updates, and changes in risk factors. (See Geron Corp stock charts on TipRanks). Q2 Financial Results Geron reported revenue of $107,000 for Q2 2021, compared to $43,000 in the same quarter last year. The company’s main sources of revenue currently are license fees and royalties.
https://www.tipranks.com/news/understanding-changes-in-gerons-risk-factors?utm_source=advfn.com&utm_medium=referral